Gene: ADAMTS13
Official Full Name: ADAM metallopeptidase with thrombospondin type 1 motif 13provided by HGNC
Gene Summary: This gene encodes a member of a family of proteins containing several distinct regions, including a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. The enzyme encoded by this gene specifically cleaves von Willebrand Factor (vWF). Defects in this gene are associated with thrombotic thrombocytopenic purpura. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO31228 | ADAMTS13 Knockout cell line (HCT 116) | Human | ADAMTS13 | 1:2~1:4 | Negative | Online Inquiry |
KO31229 | ADAMTS13 Knockout cell line (HEK293) | Human | ADAMTS13 | 1:3~1:6 | Negative | Online Inquiry |
ADAMTS13 Gene Knockout Cell Lines are specifically engineered cellular models designed to study the ADAMTS13 gene, which encodes a metalloproteinase responsible for cleaving von Willebrand factor (VWF). This function is critical in maintaining hemostatic balance, as dysregulation can contribute to thrombotic thrombocytopenic purpura (TTP) and other coagulation disorders. These knockout cell lines completely disrupt the expression of the ADAMTS13 gene, enabling researchers to investigate the resulting physiological and pathological changes in both in vitro and in vivo systems.
The primary mechanism by which ADAMTS13 operates involves the proteolytic cleavage of ultra-large VWF multimers, preventing inappropriate platelet aggregation and thrombosis. By utilizing ADAMTS13 Gene Knockout Cell Lines, scientists can create a controlled environment to assess the effects of ADAMTS13 deficiency, uncovering the molecular pathways involved in thrombus formation and vascular health. This model is invaluable for preclinical studies aimed at developing novel therapeutic strategies for conditions arising from ADAMTS13 deficiencies.
In research settings, these cell lines provide unique advantages, including the ability to conduct gene rescue experiments, screen small-molecule inhibitors, and study the compensatory mechanisms that may arise in its absence. Additionally, they offer superior specificity and reliability compared to alternative models, such as transient knockdown approaches that lack long-term stability.
Researchers and clinicians alike will find great value in these knockout cell lines, as they facilitate a deeper understanding of thrombosis and related vascular disorders, thereby contributing to the development of targeted interventions and personalized medicine approaches. Our company prides itself on its extensive experience in cellular engineering, with a commitment to delivering high-quality, specific biological models that empower scientific research and accelerate medical advancement.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.